World Pharma Today published a piece titled “Top 5 AI Molecule Design Software Platforms in 2026,” examining the role of artificial intelligence in modern drug‑discovery workflows.
The article stresses that although modern AI models can easily generate molecular structures, turning those structures into viable drug candidates is considerably harder because a useful molecule must satisfy several constraints simultaneously, including stronger binding without losing selectivity, improved stability without compromising activity, sufficient novelty without becoming synthetically unrealistic, and better affinity.
ALSO READ | Tech Week Singapore 2026 Opens with Guest of Honour and Tokyo Data Centre Launch
